One of the most challenging problems of the 21st century, diabetes, affecting more than 21 million Americans. Tobin Smith, of NBT Equities, thinks that the investors will jump on the penny stock of Orgenesis Inc. (ORGS), a recent biotech start up that believes they can end that problem by converting a patient’s own liver cells into functional insulin producing cells, especially after he ...
15
DEC
DEC
0
Share
